Fibrosis in systemic sclerosis: emerging concepts and implications for targeted therapy.
about
Update on the pathogenesis of Scleroderma: focus on circulating progenitor cellsMicroRNAs Regulating Signaling Pathways: Potential Biomarkers in Systemic SclerosisRecent developments in myofibroblast biology: paradigms for connective tissue remodelingIncreased dermal collagen bundle alignment in systemic sclerosis is associated with a cell migration signature and role of Arhgdib in directed fibroblast migration on aligned ECMsEmerging targets for the treatment of scleroderma.Systemic sclerosis-dermatological aspects. Part 1: Pathogenesis, epidemiology, clinical findings.The roles of microRNAs on tuberculosis infection: meaning or myth?The essential autophagy gene ATG7 modulates organ fibrosis via regulation of endothelial-to-mesenchymal transition.Early growth response transcription factors: key mediators of fibrosis and novel targets for anti-fibrotic therapy.Role of endothelial-mesenchymal transition (EndoMT) in the pathogenesis of fibrotic disordersApoptosis modulation as a promising target for treatment of systemic sclerosis.A Role of Myocardin Related Transcription Factor-A (MRTF-A) in Scleroderma Related FibrosisA microrna screen to identify regulators of peritoneal fibrosis in a rat model of peritoneal dialysis.Pericytes, microvasular dysfunction, and chronic rejection.Glucagon-Like Peptide 1 Protects against Hyperglycemic-Induced Endothelial-to-Mesenchymal Transition and Improves Myocardial Dysfunction by Suppressing Poly(ADP-Ribose) Polymerase 1 Activity.Fibrosis in systemic sclerosis: common and unique pathobiology.Role of MicroRNAs in Fibrosis.Cells from the skin of patients with systemic sclerosis secrete chitinase 3-like protein 1.miRNAs in the vitreous humor of patients affected by idiopathic epiretinal membrane and macular hole.Wnt/β-catenin signaling is hyperactivated in systemic sclerosis and induces Smad-dependent fibrotic responses in mesenchymal cellsGenetic Susceptibility to Interstitial Lung Disease Associated with Systemic Sclerosis.Racial differences between blacks and whites with systemic sclerosisPotential role of human-specific genes, human-specific microRNAs and human-specific non-coding regulatory RNAs in the pathogenesis of systemic sclerosis and Sjögren's syndrome.Role of endothelial to mesenchymal transition in the pathogenesis of the vascular alterations in systemic sclerosis.Evidence for progressive reduction and loss of telocytes in the dermal cellular network of systemic sclerosisTreatment of Rapidly Progressive Systemic Sclerosis: Current and Futures PerspectivesInterfacial Adipose Tissue in Systemic Sclerosis.Understanding fibrosis in systemic sclerosis: shifting paradigms, emerging opportunities.Integration of microRNA and mRNA expression profiles in the skin of systemic sclerosis patientsPropylthiouracil prevents cutaneous and pulmonary fibrosis in the reactive oxygen species murine model of systemic sclerosis.Clinical correlates of a subset of anti-CENP-A antibodies cross-reacting with FOXE3p53-62 in systemic sclerosis.The role of microRNAs in skin fibrosis.The role of WNT10B in physiology and disease.Deconstructing fibrosis research: do pro-fibrotic signals point the way for chronic dermal wound regeneration?Autoimmunity in 2011.The long-term marriage between autoimmunity and internal medicine: a homage to Manuel Carlos Dias.Scleroderma therapy: clinical overview of current trends and future perspective.Fibroblast autophagy in fibrotic disorders.Interstitial lung diseases-can pathologists arrive at an etiology-based diagnosis? A critical update.Systemic effects of Wnt signaling.
P2860
Q26751234-BB26FB37-1485-484E-9FC4-0FECE0F4F059Q26781257-F92CA8F6-E333-4217-B029-FDD631523D48Q26863751-E5EC0052-F3FA-45A1-90F5-6341FFE6CCF0Q33853799-53D58277-182A-4418-A7E7-CFDC2878C26DQ34270856-8A8FBADD-D208-4BA5-82A4-FA8036D95793Q34295337-79C44A08-0325-4817-8760-8DAD0D8FA772Q34985202-56A0E1ED-243D-4529-84AA-251ADA8FF350Q35048942-550B9E0A-99C7-424A-8FA5-24C34D6B756CQ35101753-D50C3D4A-113C-4879-BAB3-10F669AAA087Q35168217-E6D7CC44-A50E-40E5-8340-26CC0463D0F7Q35207610-743EECD6-A107-42E8-8284-AFE5B1E0C782Q35587696-DE8860B7-0287-4482-835F-3BAB30F8EFC7Q35605375-AA199698-6434-4BBD-87D2-7CF6C7F87118Q35681643-6994EB61-C0C3-4CF0-883E-91BC9D9EF519Q35707164-23B2DE0D-670B-4E93-B106-0F4589F8D59FQ36012572-DB3E26E9-4D6A-4B85-8A2C-DD0925491B5CQ36093326-5E57E32E-3021-44BA-B721-D5BECF0FA7D4Q36250788-ADF68308-5508-4B67-B233-0D79A78203CEQ36318231-8D7EDBD3-0881-4C94-BF7D-77E3945F1034Q36558691-1376F986-C93E-40EF-8BE3-91325C9D9297Q36685226-33C51231-7E99-4414-AE88-62480AF98F76Q37129649-F949C34E-C244-441E-B571-00D338620C4DQ37165647-079DCD95-3A6D-44AE-B30E-3D194A98FAF5Q37224668-A39E2F16-DDA7-4A04-8DA6-97A5EDA14F9BQ37294119-FD129AC9-84A5-419A-B7AF-00AB75CC29A6Q37381549-0C0E4A1F-73FC-4C41-A1FF-15A311074520Q37616390-169E0EAD-9612-4991-8122-7C9311F31F9CQ37638268-95742CCA-03BD-4D07-81AB-5DF64740464DQ37648637-F2491DE1-FC26-488D-BC0F-0573BF9BA464Q37690287-6DC7711E-2005-48D8-AA65-6CECF9C0834AQ37690559-29864557-694B-4609-B200-C16E9C3EB3C0Q37691772-8F0CDA2D-1957-41D7-9A35-F7447D5C335AQ37859090-B2328181-278C-4D23-93CE-7132360353AAQ37866690-BAEB1A8C-9858-4BE8-B235-FA80B5C44251Q38021696-5B788C2D-066F-46D5-B5D8-0287F0C30401Q38028889-C598DB4A-F18F-4E2E-B610-B6FE4DB66B1AQ38046467-03BB44AF-CCBC-463C-9DDD-BEE711B7FE3AQ38047232-E440F0EF-B1BE-4775-8B0A-B59D621CA31AQ38065960-1B751729-FEA3-48BA-8BF5-99998913F04EQ38077507-1D3DB838-09A5-4E50-A6BA-97B64F9EC7D3
P2860
Fibrosis in systemic sclerosis: emerging concepts and implications for targeted therapy.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 21 September 2010
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Fibrosis in systemic sclerosis: emerging concepts and implications for targeted therapy.
@en
Fibrosis in systemic sclerosis: emerging concepts and implications for targeted therapy.
@nl
type
label
Fibrosis in systemic sclerosis: emerging concepts and implications for targeted therapy.
@en
Fibrosis in systemic sclerosis: emerging concepts and implications for targeted therapy.
@nl
prefLabel
Fibrosis in systemic sclerosis: emerging concepts and implications for targeted therapy.
@en
Fibrosis in systemic sclerosis: emerging concepts and implications for targeted therapy.
@nl
P2093
P2860
P1433
P1476
Fibrosis in systemic sclerosis: emerging concepts and implications for targeted therapy.
@en
P2093
John Varga
Swati Bhattacharyya
Warren G Tourtellotte
P2860
P304
P356
10.1016/J.AUTREV.2010.09.015
P577
2010-09-21T00:00:00Z